FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2169620187> ?p ?o ?g. }

• W2169620187 endingPage "727" @default.
• W2169620187 startingPage "717" @default.
• W2169620187 abstract "Dipeptide monoester prodrugs of floxuridine were synthesized, and their chemical stability in buffers, resistance to glycosidic bond metabolism, affinity for PEPT1, enzymatic activation and permeability in cancer cells were determined and compared to those of mono amino acid monoester floxuridine prodrugs. Prodrugs containing glycyl moieties were the least stable in pH 7.4 buffer (t1/2 < 100 min). The activation of all floxuridine prodrugs was 2- to 30-fold faster in cell homogenates than their hydrolysis in buffer, suggesting enzymatic action. The enzymatic activation of dipeptide monoester prodrugs containing aromatic promoieties in cell homogenates was 5- to 20-fold slower than that of other dipeptide and most mono amino acid monoester prodrugs (t1/2 ∼ 40 to 100 min). All prodrugs exhibited enhanced resistance to glycosidic bond metabolism by thymidine phosphorylase compared to parent floxuridine. In general, the 5′-O-dipeptide monoester floxuridine prodrugs exhibited higher affinity for PEPT1 than the corresponding 5′-O-mono amino acid ester prodrugs. The permeability of dipeptide monoester prodrugs across Caco-2 and Capan-2 monolayers was 2- to 4-fold higher than the corresponding mono amino acid ester prodrug. Cell proliferation assays in AsPC-1 and Capan-2 pancreatic ductal cell lines indicated that the dipeptide monoester prodrugs were equally as potent as mono amino acid prodrugs. The transport and enzymatic profiles of 5′-l-phenylalanyl-l-tyrosyl-floxuridine, 5′-l-phenylalanyl-l-glycyl-floxuridine, and 5′-l-isoleucyl-l-glycyl-floxuridine suggest their potential for increased oral uptake, delayed enzymatic bioconversion and enhanced resistance to metabolism to 5-fluorouracil, as well as enhanced uptake and cytotoxic activity in cancer cells, attributes that would facilitate prolonged systemic circulation for enhanced therapeutic action." @default.
• W2169620187 created "2016-06-24" @default.
• W2169620187 creator A5036898947 @default.
• W2169620187 creator A5043907978 @default.
• W2169620187 creator A5085453188 @default.
• W2169620187 date "2008-07-25" @default.
• W2169620187 modified "2023-10-10" @default.
• W2169620187 title "Enhanced Cancer Cell Growth Inhibition by Dipeptide Prodrugs of Floxuridine: Increased Transporter Affinity and Metabolic Stability" @default.
• W2169620187 cites W102725257 @default.
• W2169620187 cites W1486882165 @default.
• W2169620187 cites W1486904141 @default.
• W2169620187 cites W1508081254 @default.
• W2169620187 cites W1543510859 @default.
• W2169620187 cites W1559370499 @default.
• W2169620187 cites W1776448019 @default.
• W2169620187 cites W1965083830 @default.
• W2169620187 cites W1971348017 @default.
• W2169620187 cites W1976297946 @default.
• W2169620187 cites W1978211222 @default.
• W2169620187 cites W1984153473 @default.
• W2169620187 cites W1997045896 @default.
• W2169620187 cites W2010005339 @default.
• W2169620187 cites W2012355463 @default.
• W2169620187 cites W2015445088 @default.
• W2169620187 cites W2025975417 @default.
• W2169620187 cites W2026269931 @default.
• W2169620187 cites W2027896347 @default.
• W2169620187 cites W2038750327 @default.
• W2169620187 cites W2041584025 @default.
• W2169620187 cites W2050322809 @default.
• W2169620187 cites W2059477760 @default.
• W2169620187 cites W2063722936 @default.
• W2169620187 cites W2068178457 @default.
• W2169620187 cites W2072131452 @default.
• W2169620187 cites W2083274261 @default.
• W2169620187 cites W2089700880 @default.
• W2169620187 cites W2093038568 @default.
• W2169620187 cites W2094026193 @default.
• W2169620187 cites W2097863702 @default.
• W2169620187 cites W2102221021 @default.
• W2169620187 cites W2110387631 @default.
• W2169620187 cites W2124549875 @default.
• W2169620187 cites W2129960499 @default.
• W2169620187 cites W2132811836 @default.
• W2169620187 cites W2136817236 @default.
• W2169620187 cites W2150535357 @default.
• W2169620187 cites W2151832939 @default.
• W2169620187 cites W2171323410 @default.
• W2169620187 cites W2255539187 @default.
• W2169620187 cites W2327253704 @default.
• W2169620187 cites W61002655 @default.
• W2169620187 doi "https://doi.org/10.1021/mp800008c" @default.
• W2169620187 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2659690" @default.
• W2169620187 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/18652477" @default.
• W2169620187 hasPublicationYear "2008" @default.
• W2169620187 type Work @default.
• W2169620187 sameAs 2169620187 @default.
• W2169620187 citedByCount "65" @default.
• W2169620187 countsByYear W21696201872012 @default.
• W2169620187 countsByYear W21696201872013 @default.
• W2169620187 countsByYear W21696201872014 @default.
• W2169620187 countsByYear W21696201872015 @default.
• W2169620187 countsByYear W21696201872016 @default.
• W2169620187 countsByYear W21696201872017 @default.
• W2169620187 countsByYear W21696201872018 @default.
• W2169620187 countsByYear W21696201872019 @default.
• W2169620187 countsByYear W21696201872020 @default.
• W2169620187 countsByYear W21696201872021 @default.
• W2169620187 countsByYear W21696201872022 @default.
• W2169620187 countsByYear W21696201872023 @default.
• W2169620187 crossrefType "journal-article" @default.
• W2169620187 hasAuthorship W2169620187A5036898947 @default.
• W2169620187 hasAuthorship W2169620187A5043907978 @default.
• W2169620187 hasAuthorship W2169620187A5085453188 @default.
• W2169620187 hasBestOaLocation W21696201871 @default.
• W2169620187 hasConcept C108215921 @default.
• W2169620187 hasConcept C126322002 @default.
• W2169620187 hasConcept C185592680 @default.
• W2169620187 hasConcept C2776694085 @default.
• W2169620187 hasConcept C2779138802 @default.
• W2169620187 hasConcept C2779598120 @default.
• W2169620187 hasConcept C2780456651 @default.
• W2169620187 hasConcept C515207424 @default.
• W2169620187 hasConcept C55493867 @default.
• W2169620187 hasConcept C71924100 @default.
• W2169620187 hasConceptScore W2169620187C108215921 @default.
• W2169620187 hasConceptScore W2169620187C126322002 @default.
• W2169620187 hasConceptScore W2169620187C185592680 @default.
• W2169620187 hasConceptScore W2169620187C2776694085 @default.
• W2169620187 hasConceptScore W2169620187C2779138802 @default.
• W2169620187 hasConceptScore W2169620187C2779598120 @default.
• W2169620187 hasConceptScore W2169620187C2780456651 @default.
• W2169620187 hasConceptScore W2169620187C515207424 @default.
• W2169620187 hasConceptScore W2169620187C55493867 @default.
• W2169620187 hasConceptScore W2169620187C71924100 @default.
• W2169620187 hasIssue "5" @default.
• W2169620187 hasLocation W21696201871 @default.
• W2169620187 hasLocation W21696201872 @default.

• next